Opinion

Video

Evaluating the Benefits of Cretostimogene Plus Pembrolizumab for BCG-Unresponsive NMIBC Management

Author(s):

Trinity Bivalacqua, MD, PhD,Mark D. Tyson, MD, MPH

Panelists discuss how the combination therapy of cretostimogene plus pembrolizumab offers a promising new approach for managing BCG-unresponsive non-muscle-invasive bladder cancer, highlighting its potential benefits and the implications of its FDA Breakthrough Therapy Designation for clinical practice.

Video content above is prompted by the following questions:

  • In your opinion, what does cretostimogene plus pembrolizumab combination therapy offer to the management of BCG-unresponsive NMIBC?
  • Cretostimogene plus pembrolizumab received an FDA Breakthrough Therapy Designation in May 2023. What is important for physicians to know or understand about this designation?
Related Videos
Doctor consulting patient | Image Credit: © Liudmila Dutko - stock.adobe.com
4 experts in this video
4 experts in this video
Female doctor typing on her laptop computer in medical office | Image Credit: © Rostislav Sedlacek - stock.adobe.com
4 experts in this video
4 experts in this video
Rebecca A. Campbell, MD, answers a question during a Zoom video interview
Joshua J. Meeks, MD, PhD, gives an answer during a Zoom video interview
Related Content
FDA approves mitomycin intravesical solution for recurrent LG-IR-NMIBC
June 12th 2025

FDA approves mitomycin intravesical solution for recurrent LG-IR-NMIBC

Hannah Clarke
The approval is supported by findings from the phase 3 ENVISION trial.
medical depiction of bladder cancer
May 31st 2023

Bladder Cancer Awareness Month: Dr. Kamat highlights the state of bladder cancer care

Urology Times staff
In this episode, Ashish M. Kamat, MD, MBBS, highlights the state of bladder cancer care in recognition of Bladder Cancer Awareness Month.
Human urinary bladder | Image Credit: © magicmine - stock.adobe.com
June 9th 2025

En bloc resection of bladder tumor: Is it the way forward?

Jeremy Teoh, MBBS, FRCSEd (Urol), FCSHK, FHKAM (Surgery)
"As urologists, we are the gatekeepers, and we must always perform the best possible surgery to optimize oncological outcomes," writes Jeremy Teoh, MBBS, FRCSEd (Urol), FCSHK, FHKAM (Surgery).
Speaking of Urology Podcast: Dr. Ritch and Dr. Katz discuss new bladder cancer management app
December 7th 2021

Speaking of Urology Podcast: Dr. Ritch and Dr. Katz discuss new bladder cancer management app

Urology Times staff
“It's not a replacement for clinical judgment, obviously. But at the end of the day, the idea is that it shows you what your next steps are based on what the American Urological Association and [Society of Urologic Oncology] guidelines are for non-muscle invasive bladder cancer,” Chad R. Ritch, MD, MBA, FACS.
FDA updates in urology: May 2025
June 2nd 2025

FDA updates in urology: May 2025

Hannah Clarke
A recap of the FDA submissions and regulatory decisions in urology from May 2025.
Human urinary bladder | Image Credit: © magicmine - stock.adobe.com
June 1st 2025

NIAGARA: ctDNA analysis highlights durvalumab’s impact in MIBC

Benjamin P. Saylor
The findings also lend further credence to the muscle-invasive bladder cancer treatment regimen, investigators reported.
© 2025 MJH Life Sciences

All rights reserved.